Life Technologies Announces SFDA Clearance for its 3500xL Dx Genetic Analyzer in China and the Launch of 10 Assays from its

Life Technologies Announces SFDA Clearance for its 3500xL Dx Genetic Analyzer
  in China and the Launch of 10 Assays from its Joint Venture with Daan Gene

PR Newswire

SHANGHAI, March 27, 2013

SHANGHAI, March 27, 2013 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced that its Applied Biosystems 3500xL Dx Genetic
Analyzer has been approved by China's State Food and Drug Administration
(SFDA) for clinical diagnostic use in China and the launch of 10 Assays from
its joint venture with Daan Gene. The development marks a major extension of
Life Technologies' capabilities to serve the clinical end market in China with
Sanger-based solutions.

The 3500xL Dx is an automated 24 capillary-based Sanger Sequencer designed for
a wide range of sequencing applications. It delivers high quality performance,
higher throughput and increased productivity for clinical laboratories around
the world.

Together with Life Technologies' genetic analyzer 3500 Dx that was approved by
SFDA for IVD use in 2011 in China, the 3500 series genetic analyzers are
intended for use in a wide range of applications in the process of clinical
research, including de novo sequencing and mutational profiling as well as HLA
typing. The newly expanded offering of both the 3500 Dx and the 3500xL Dx
provides hospitals of all sizes the flexibility they need to meet their unique
throughput demands.

Based on the 3500 Dx series platform, ten assays have been developed or
licensed by Guangzhou Life Technologies DaAn Diagnostics Co. Ltd, a joint
venture that established in 2012 between Life Technologies and Daan Gene Co.
Ltd. of Sun Yat Sen University. These assays will be used for genotypic and
drug resistance testing, cancer mutation identification and the prenatal
chromosome disorder detection. Currently, nine out of the ten assays are
Research Use Only kits and the other one that can be used in Trisomy 21
prenatal screening for Down syndrome is SFDA registered. The company is
currently conducting clinical trials and is actively seeking the SFDA approval
for the remaining nine kits.

"The current approval of the 3500xL Dx by SFDA emphasizes Life Technologies'
success in pursuing regulatory pathways for our diagnostics laboratory
instruments as well as our vision to becoming a global leader in the molecular
diagnostics industry," said Ronnie Andrews, president of Medical Sciences at
Life Technologies.

"As in other countries, China is facing the challenges of fighting with
infectious diseases like HBV, TB, HCV and HIV, as well as various
genetic-based diseases like lung cancer, breast cancer, and ovarian cancers,
etc. The early detection and treatment of these diseases will greatly
increase the recovery and survival rate of patients," said Dr. Siddhartha
Kadia, president of Life Technologies Greater China. "Life Technologies is
committed to bring more medical diagnostic products, like the 3500xL Dx
genetic analyzer to support clinical research and diagnostics, which are
expected to lead to a higher quality of life for Chinese people and more
economical healthcare solutions."

Applied Biosystems Sanger Sequencers supplied the technology that powered the
Human Genome Project, and Sanger instruments remain the sequencing
"gold-standard" for accuracy, reliability and ease of use. The participation
of the sequencing technologies in clinical diagnostics is reshaping the
disease treatment paradigm worldwide. 

Additional products offered by Life Technologies for the molecular diagnostics
lab market in China include: the Applied Biosystem 7500, 7500 Fast Dx,
StepOne, StepOne Plus, ViiA7 Dx qPCR series. Veriti™ Dx Thermal Cycler is in
the process of SFDA registration in China.

About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
that is committed to providing the most innovative products and services to
leading customers in the fields of scientific research, genetic analysis and
applied sciences. With a presence in more than 180 countries, the company's
portfolio of 50,000 end-to-end solutions is secured by more than 5,000 patents
and licenses that span the entire biological spectrum -- scientific
exploration, molecular diagnostics, 21^stcentury forensics, regenerative
medicine and agricultural research. Life Technologies has approximately 10,000
employees and had sales of $3.8 billion in 2012.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made byLife Technologies with the Securities and Exchange
Commission.Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact:
Vivian Lv, External Affairs & Corporate Communications
+86 10 8446 1901

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.